Lineage Cell Therapeutics, Inc.
- Jurisdiction
United States - LEI
5299002BI4W22SDF8R25 - ISIN
US53566P1093 (LCTX )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
4
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
5
/ 7
Profile
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. Read full profile
Fundamentals
- Net revenue
€9.31M - Gross margin
97.6% - EBIT
-€30.05M - EBIT margin
-322.8% - Net income
-€34.89M - Net margin
-374.8%
Statement period: - (published )
Estimates
| Fiscal Year | Net revenue | Net income |
|---|---|---|
|
|
| |
|
|
| |
|
|
|
Stock price
Dividends
- Last dividend amount
-
$0.08 - Ex date
-
Analyst ratings
No analyst ratings available
Insider Transactions
No insider transactions in the last 90 days. View older insider transactions
Earnings Calls
Investor transactions
| Name | Shares | Value | Last change | Change type |
|---|---|---|---|---|
| Peter Brown |
|
|
|
Buy |
Earnings Calls
Latest earnings call: May 9, 2024 (Q1 2024)